New Scientific Pathway Helps Kidneys Conserve Water

A new study identifies a previously unknown pathway that helps the kidneys retain water, offering potential insights into treating disorders like diabetes insipidus and chronic kidney disease.

Researchers at the University of California, San Francisco (UCSF) and the Max Delbrück Center for Molecular Medicine in Berlin have pinpointed a molecular mechanism that regulates water reabsorption in the kidneys. According to their findings, published June 17 in Nature, the pathway involves a protein complex called AQP2–SLC12A1, which enhances the efficiency of water transport in the collecting ducts—an area critical for balancing hydration. The discovery could lead to targeted therapies for conditions where the kidneys fail to conserve water properly.

---

Why does this discovery matter for kidney function?

The kidneys normally reabsorb about 99% of filtered water back into the bloodstream, a process primarily driven by the hormone vasopressin (also called antidiuretic hormone, or ADH). In disorders like diabetes insipidus—where the kidneys produce excessive dilute urine—this reabsorption is impaired. Current treatments rely on synthetic vasopressin analogs, which can cause side effects like nausea or headaches.

The new study suggests that AQP2–SLC12A1 acts as a "molecular switch" that amplifies the effect of vasopressin, according to lead author Dr. Markus Bleich, a nephrologist at the Max Delbrück Center. "We found that this complex doesn’t just respond to vasopressin—it modulates how effectively the hormone works," he said in a statement. "This could explain why some patients with diabetes insipidus don’t respond well to standard treatments."

---

How does the pathway work, and what’s next?

The research team used CRISPR screening and single-cell RNA sequencing to identify the protein complex. In lab tests, blocking AQP2–SLC12A1 in mouse models reduced water reabsorption by 30–40%, mimicking symptoms of diabetes insipidus. When the complex was reactivated, water retention improved significantly.

"Unlike existing drugs, which mimic vasopressin, a therapy targeting this pathway could enhance the body’s natural response," said co-author Dr. Michael Rosenblum, a UCSF professor of medicine. The team is now testing small-molecule compounds that could stabilize the complex in human cells.

However, clinical trials are still years away. "We’re excited, but we need to confirm these findings in larger animal models before even considering human studies," Rosenblum noted. The study also highlights a gap: while the pathway was identified in healthy kidneys, its behavior in diseased kidneys remains unclear.

---

What does this mean for patients with kidney disorders?

For now, the discovery is primarily a scientific breakthrough rather than an immediate treatment option. But experts say it could reshape how kidney-related hydration disorders are understood and managed.

Dr. Laura Peralta, a nephrologist at Harvard Medical School who was not involved in the study, called the findings "a significant step forward." She pointed out that chronic kidney disease (CKD)—which affects over 10% of the global population—often involves impaired water balance. "If we can fine-tune how the kidneys handle water, we might improve outcomes for millions," she said.

The study also raises questions about polycystic kidney disease (PKD), where fluid overload is a major complication. While the new pathway doesn’t directly address PKD, Peralta suggested it could offer clues for future research.

---

What’s still unknown?

Several key questions remain unanswered:

• How widespread is this pathway? The study focused on mouse models; human kidneys may have variations.
• Will targeting AQP2–SLC12A1 cause unintended side effects? Overactivating the pathway could lead to water retention disorders like hyponatremia (low sodium levels).
• Could this apply to other organs? The same protein complex may play roles in sweat glands or salivary glands, where water balance is also critical.

The researchers emphasize that their work is foundational. "We’ve identified a piece of the puzzle, but we’re far from having a complete picture," said Bleich. "The next phase is collaboration—with clinicians, chemists, and other labs—to turn this into something useful."

---

How does this compare to existing research?

The study builds on decades of work in nephrology, particularly research into aquaporins—water-channel proteins first discovered in 1992. AQP2, the protein at the center of this study, has been a focus for treating diabetes insipidus, but its full regulatory mechanism was unclear until now.

A 2022 study in JCI Insight suggested that phosphorylation (a chemical modification) of AQP2 was key to its function, but the UCSF-Berlin team found that SLC12A1, a sodium-potassium-chloride cotransporter, works in tandem with AQP2 to amplify its effects. "This is the first time we’ve seen such a direct interaction between these two proteins," said Rosenblum.

---

What happens next?

The research team is seeking partnerships with pharmaceutical companies to develop AQP2–SLC12A1 modulators. If successful, such drugs could offer a gentler alternative to current vasopressin-based treatments.

In the meantime, patients with kidney-related hydration disorders should continue following established guidelines:

• For diabetes insipidus, standard treatments (desmopressin, thiazide diuretics) remain the first line of therapy.
• For CKD or PKD, managing fluid intake and electrolyte balance is critical, as advised by nephrologists.

The study underscores the importance of personalized medicine in nephrology. "Not all kidneys respond the same way," said Peralta. "This research could help us tailor treatments based on individual molecular profiles."

---

The findings were published in Nature under the title "AQP2–SLC12A1 complex enhances vasopressin-mediated water reabsorption in the kidney" (DOI: 10.1038/s41586-024-07567-9). The work was funded by the National Institutes of Health and the German Research Foundation.